Navigation Links
Sangui and SastoMed Complement Licensing Agreement in View of Increasing Sales Success
Date:8/27/2012

WITTEN, Germany, August 27, 2012 /PRNewswire/ --

Sangui BioTech GmbH and SastoMed GmbH cordially adjusted the existing sales strategy as the introduction of Granulox to professional circles proves to be increasingly successful. In consideration of corresponding contributions the existing licensing contract was partially complemented resulting in the following conditions:

As licensor SanguiBioTech GmbH is awarded a fixed licensing fee as a percentage of each and every external revenues incurred by SastoMed from sales of the Granulox product (based on SastoMed selling prices). The percentage ranges in the uppermost zone of what is usually granted in the pharmaceutical and medical products industries and thus well above the average licensing rate of 7.5% of sales revenues as calculated by market analysts. In addition and complementing this basic agreement the percentage will be permanently increased by one fourth of the current rate as soon as cumulated sales revenues at SastoMed will have exceeded the total of €50,000,000.

As shareholder SanguiBioTech GmbH will benefit additionally from all future dividends to be paid by the subsidiary according to the percentage of its stake in SastoMed that is at a rate of 25%. Should eventually all the shares of SastoMed GmbH be sold in total to a third party, the existing licensing contract with SanguiBioTech GmbH will persist unchanged.

"This amendment of our licensing contract", emphasized Hubertus Schmelz, Managing Director of SanguiBioTech GmbH, "is another token of the close and cordial cooperation based on mutual trust and aiming at our joint success. Our business model proves its worth not least because of the professional and effective work of our partners which meets our support in every respect."

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB marketplace (http://www.otcmarkets.com: SGBI) and the OTC market of Hamburg-Hannover stock exchanges. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions.  Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:
Joachim Fleing
Phone: +49(179)7963472
Fax:   +49(2302)915191
e-mail: fleing@sangui.de


'/>"/>
SOURCE Sangui Bio Tech International Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management
2. CE Mark Granted for Wound Spray Based on Sangui Patent
3. Sangui Bio Tech International Inc. - Over 500 Customers: Granulox Sales Ahead of Planning
4. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
5. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
6. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
7. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
8. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
11. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... AUSTIN, Texas, March 29, 2017  Vermillion, Inc. ... gynecologic disease, reported on its results for the ... 2016. "2016 marked a pivotal year ... ACOG guideline inclusion, international distribution agreements, major reimbursement ... in network payer agreements. In addition we cleared ...
(Date:3/29/2017)... - Last year,s petition to the White House signed by ... to generate awareness on the importance of new organic medicines and ... market place. ... Earlier this month Health Advance (OTC PINK: HADV ... products, announced its endeavors on this generally recognized as safe ...
(Date:3/29/2017)... ... March 29, 2017 , ... (March ... International Mexico has been approved as an active member of the Mexican ... protection among distributers and consumers in relationship marketing. This professional organization fosters loyal ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
Breaking Biology News(10 mins):